scholarly journals Prediction of dialysis patients in Japan : Based on Japanese Society for Dialysis Therapy Registry

2012 ◽  
Vol 45 (7) ◽  
pp. 599-613 ◽  
Author(s):  
Shigeru Nakai ◽  
Kenji Wakai ◽  
Kunihiro Yamagata ◽  
Kunitoshi Iseki ◽  
Yoshiharu Tsubakihara
Keyword(s):  
Japanese Society ◽  
Dialysis Patients ◽  
Dialysis Therapy

scholarly journals Calculation of expected remaining lifetime of dialysis patients in Japan

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Shigeru Nakai ◽  
Atsushi Wada ◽  
Kenji Wakai ◽  
Masanori Abe ◽  
Kosaku Nitta
Keyword(s):  
Survival Rate ◽  
Life Table ◽  
Japanese Society ◽  
Therapeutic Agents ◽  
Diabetic Patients ◽  
Dialysis Patients ◽  
Dialysis Therapy ◽  
Data Registry ◽  
Improved Outcomes ◽  
Registry Database

Abstract Background The expected remaining lifetime of dialysis patients in Japan was only reported in 2003 and has not been reported thereafter. From 2003 to the present, several new therapeutic agents have been introduced. These events may have improved outcomes for dialysis patients. Thus, expected remaining lifetime of dialysis patients in Japan was newly calculated in 2015. Methods The Japanese Society for Dialysis Therapy Renal Data Registry database was used for analyses. From this database, the following three indexes were compiled: the number of surviving dialysis patients (198,125 males and 111,962 females) at the end of 2014 and the number of surviving (179,649 males and 101,758 females) and dead (18,044 males and 111,417 females) patients at the end of 2015. Based on these values, expected remaining lifetime at 1-year increment was calculated using the life table method. Results Excerpts of the calculated expected remaining lifetimes of patients aged 60 years were as follows: 11.9 years for males and 14.1 years for females. These expected remaining lifetimes were 1.1 to 1.2 times as compared with those in 2003. Meanwhile, expected remaining lifetime of diabetic patients was 10.8 years for males and 12.5 years for females and that of nondiabetic patients was 13.0 years for males and 15.0 years for females. Conclusion Expected remaining lifetime of dialysis patients in Japan in 2015 was 10–20% longer than that in 2003. These results suggest that advances in dialysis technologies during this 12-year period improved the survival rate of dialysis patients.

scholarly journals Japanese Society for Dialysis Therapy Clinical Guideline for “Maintenance Hemodialysis: Hemodialysis Prescriptions”

2015 ◽  
Vol 19 ◽  
pp. 67-92 ◽  
Author(s):  
Yuzo Watanabe ◽  
Hideki Kawanishi ◽  
Kazuyuki Suzuki ◽  
Shigeru Nakai ◽  
Kenji Tsuchida ◽  
...  
Keyword(s):  
Japanese Society ◽  
Clinical Guideline ◽  
Maintenance Hemodialysis ◽  
Dialysis Therapy

MO757COMPARISON OF ANTI-COAGULATION AND NO ANTI-COAGULATION IN DIALYSIS PATIENTS WITH ATRIAL FIBRILLATION: A SINGLE CENTER RETROSPECTIVE STUDY

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Jun Young Lee ◽  
Jae Won Yang ◽  
Jae Seok Kim ◽  
Seong Ok Choi ◽  
Byoung Geun Han
Keyword(s):  
Atrial Fibrillation ◽  
Cox Regression ◽  
Dialysis Patients ◽  
Dialysis Therapy ◽  
Cox Regression Analysis ◽  
Significant Difference ◽  
Baseline Characteristics ◽  
Stage Renal Disease ◽  
End Stage ◽  
Risk And Benefit

Abstract Background and Aims Atrial fibrillation (AF) is common arrhythmia in end stage renal disease patients. Although, the need of anticoagulation to prevent stroke and thromboembolism is increasing, the efficacy of anticoagulation is not proven in most of study. We retrospectively analyzed the risk and benefit of anticoagulation in dialysis patients with AF. Method By using medical record, we retrospectively analyzed all data of 99 patients who received dialysis therapy and diagnosed AF. Results Among 99 patients who diagnosed AF with dialysis 36 patients received anticoagulation (17 coumadin, 19 apixaban 2.5mg bid), 63 patients received no anticoagulation. There was no significant difference of baseline characteristics between anticoagulation, and no anticoagulation patients. Although no anticoagulation group experienced more all-cause (39.7% vs 32.4%, p=0.572) and cardiovascular mortality (17.6% vs 10.8%, p=0.197) than anticoagulation group it was not statistically significant. Compared to apixaban 2.5mg bid patients, coumadin anticoagulation patients experienced more frequent mfig ajor adverse cardiovascular events (35.3% vs 15.8%, p=0.109) but it was not statistically significant in multi variate Cox regression analysis (Hazard ratio 1.143, 95% Confidence Interval 0.503-2.597). Conclusion Apixaban 2.5mg bid was not inferior than coumadin considering risk and benefit of anticoagulation in dialysis patients.

scholarly journals Shared decision making for the initiation and continuation of dialysis: a proposal from the Japanese Society for Dialysis Therapy

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Kazuyoshi Okada ◽  
Ken Tsuchiya ◽  
Ken Sakai ◽  
Takahiro Kuragano ◽  
Akiko Uchida ◽  
...  
Keyword(s):  
Decision Making ◽  
Shared Decision Making ◽  
Japanese Society ◽  
Healthcare Management ◽  
Maintenance Hemodialysis ◽  
Decision Making Process ◽  
Healthcare Team ◽  
Shared Decision ◽  
Dialysis Therapy ◽  
Terminal Stage

Abstract Background In Japan, forgoing life-sustaining treatment to respect the will of patients at the terminal stage is not stipulated by law. According to the Guidelines for the Decision-Making Process in Terminal-Stage Healthcare published by the Ministry of Health, Labor and Welfare in 2007, the Japanese Society for Dialysis Therapy (JSDT) developed a proposal that was limited to patients at the terminal stage and did not explicitly cover patients with dementia. This proposal for the shared decision-making process regarding the initiation and continuation of maintenance hemodialysis was published in 2014. Methods and results In response to changes in social conditions, the JSDT revised the proposal in 2020 to provide guidance for the process by which the healthcare team can provide the best healthcare management and care with respect to the patient's will through advance care planning and shared decision making. For all patients with end-stage kidney disease, including those at the nonterminal stage and those with dementia, the decision-making process includes conservative kidney management. Conclusions The proposal is based on consensus rather than evidence-based clinical practice guidelines. The healthcare team is therefore not guaranteed to be legally exempt if the patient dies after the policies in the proposal are implemented and must respond appropriately at the discretion of each institution.

Carpal Tunnel Surgery as Proxy for Dialysis-Related Amyloidosis: Results from the Japanese Society for Dialysis Therapy

2014 ◽  
Vol 39 (5) ◽  
pp. 449-458 ◽  
Author(s):  
Junichi Hoshino ◽  
Kunihiro Yamagata ◽  
Shinichi Nishi ◽  
Shigeru Nakai ◽  
Ikuto Masakane ◽  
...  
Keyword(s):  
Carpal Tunnel ◽  
Japanese Society ◽  
Dialysis Therapy ◽  
Carpal Tunnel Surgery

scholarly journals Japanese Society for Dialysis Therapy Clinical Guideline for “Hemodialysis Initiation for Maintenance Hemodialysis”

2015 ◽  
Vol 19 ◽  
pp. 93-107 ◽  
Author(s):  
Yuzo Watanabe ◽  
Kunihiro Yamagata ◽  
Shinichi Nishi ◽  
Hideki Hirakata ◽  
Norio Hanafusa ◽  
...  
Keyword(s):  
Japanese Society ◽  
Clinical Guideline ◽  
Maintenance Hemodialysis ◽  
Dialysis Therapy
Sign in / Sign up

Export Citation Format

Share Document